Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6574 霈方. Please read: https://finlab.finance/en/setup?stock=6574

No install, open FinLab Studio

6574

霈方 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

strong quality, discounted valuation.

1 active signal

Revenue ≥20%

This page refreshes daily after the close. Add 霈方 to your watchlist to track signal changes on your next visit.

Is 霈方 a buy? Fundamentals and valuation first

Top-tier profitability.Operating margin beats ~98% of the market. Latest quarterly ROE ≈ 8.1%.
Valuation is low.PE is in the 15th market percentile; within its own history, PE is around the 3th percentile.
Foreign investors are net selling.Foreign 20-day net flow ≈ -2.3% of volume (net sell).
Strong revenue growth.Latest monthly revenue YoY ≈ 39.4%, above the 20% growth threshold.
Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Neutral -0.09

BearishNeutralBullish

Institutional rotation, concentration steady — neutral

Institutional rotation, concentration steady — neutral
群益金鼎-丹鳳 holds 102 lots
sellers have 101 lots left, ~65 sessions to clear

Window from 2026-01-17 · Price +64% · branches to 2026-06-17· TDCC to 2026-06-12

Largest holder 群益金鼎-丹鳳 has accumulated 102 lots since the start (sold 1%), still adding.
Main distributor 美林 peaked at 47 lots, has sold 68%, 15 left, ~12 sessions to clear at the recent pace.
TDCC big holders (absolute) >1000-lot holders +0.00pp, mid holders -1, retail +2.90pp — drifting down to retail.
Foreign hedge-desk net short Net short -135 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).

Branch inventory reconstruction

Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.

Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.

Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.

Accumulating

群益金鼎-丹鳳(牛牛牛)亞-網路美商高盛永豐金-市政台新-新莊台新-吉利

Distributing

美林元大-向上新光-台南新光-台中摩根大通永豐金-板新

Desks

own scale

統一-三多國泰-敦南台新-高雄富邦-仁愛

Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline

Branch details Unit: lots

Accumulating

群益金鼎-丹鳳 +102

sold 1%· still adding
(牛牛牛)亞-網路 +100

sold 16%· still adding
美商高盛 +66

sold 11%· still adding
永豐金-市政 +34

sold 0%· still adding
台新-新莊 +32

sold 0%· still adding
台新-吉利 +31

sold 0%· still adding

Distributing

美林 15 left

sold 68%· ~12 sessions to clear
元大-向上 23 left

sold 34%· paused recently
新光-台南 16 left

sold 43%· paused recently
新光-台中 12 left

sold 45%· ~24 sessions to clear
摩根大通 8 left

sold 64%· ~40 sessions to clear
永豐金-板新 13 left

sold 32%· ~65 sessions to clear

Desks

統一-三多 -795

unclassified
國泰-敦南 -102

day-trade · selling pressure
台新-高雄 -46

unclassified
富邦-仁愛 -41

unclassified

Still selling 101 lots ~65 sessions to bottom at most

Recent buy/sell force +204 absorbed / -58 sold buyers slightly ahead

Hedge-desk net short -8 lots potential cover-buying, not selling pressure

TDCC big holders · absolute-holding cross-check

>1000-lot holder share Retail (<400 lots) share Price (right axis)

Weak direction: big-holder share fell while retail share rose.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 39.43%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

32 historical occurrences (since 2017-09-04)

120 days after: historical avg +3.2%

20-day +10.89%

60-day +11.76%

120-day +3.2%

20-day

60-day

120-day

Win

61.5%

50%

44.4%

Sample

Median

+1.45%

+1.18%

-6.52%

Excess

+9.54%

+3.8%

-5.56%

Beat mkt rate

61.5%

58.3%

44.4%

Over 9 occurrences, 120-day forward avg gained 3.2%, lagged the market by 5.56 pts; win rate 44.4%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

0-20 +50% Now

20-40 +10.1%

40-60 +11.6%

60-80 +15.3%

80-100 +6.7%

PE percentile band	Sample days	240-day avg return	Median	Win rate	Avg excess (vs index)
0-20 You are here	145	+50%	+38.2%	100%	-4.1%
20-40	100	+10.1%	+5.6%	66%	-34%
40-60	151	+11.6%	+11.1%	94%	-18.3%
60-80	273	+15.3%	+3.8%	55.7%	-3.4%
80-100	476	+6.7%	+5.2%	67%	+3.6%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 12.37, at the 2.6th percentile of its own history (0-20 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation

Momentum

Cheap (own-history bottom 1/3)

Mid

Expensive (own-history top 1/3)

60-day momentum up

+21.8%

Win rate 77.6% Excess -0.4%

147d

+3.3%

Win rate 61.8% Excess -11.3%

68d

-0.1%

Win rate 49.5% Excess -3.8%

366d

60-day momentum down

Now

+21.2%

Win rate 59% Excess -5.5%

139d

+6.4%

Win rate 84.6% Excess -14.8%

104d

+2.2%

Win rate 64% Excess +2.9%

172d

Currently in “Cheap (own-history bottom 1/3) × 60-day momentum down”: across 139 historical days, 120-day forward avg gained 21.2%, win rate 59%, lagged the market by 5.5%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

6 times historically; 60-day forward avg +10.52%, win rate 50%, beating the market by +1.39 pts on average.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

What does 霈方 do? Company profile

生技醫療業／應用生技／美容保養與醫學美容服務上櫃

Overview

6574 對應霈方國際股份有限公司，為台灣櫃買中心上櫃普通股，非 ETF、ETN、權證或特別股。公司成立於 2002-10-02，總部位於台北市大安區忠孝東路四段310號6樓，電話 02-2775-5566，統一編號 80281973。股票於 2017-09-04 在證券櫃檯買賣中心掛牌交易；鉅亨網、Goodinfo 與環球生技資料均顯示公司為上櫃公司，產業歸類為生技醫療／應用生技。董事長、總經理與發言人為呂慶盛。實收資本額約新台幣 2.199 億元，已發行普通股約 21,990,000 股；2024 年報揭露 2025 年 4 月底合併員工人數 160 人，2024 年底員工 220 人，2023 年底 284 人。2024 年報揭露主要股東包括晶硯生活股份有限公司持股 17.69%、台灣茵蝶美學有限公司 17.66%、呂慶盛 11.00%、呂美珍 10.33%、台灣蕾舒翠愛美有限公司 9.93%、台灣配方投資控股有限公司 9.33%、王兆杰 3.33%、呂金發 2.93%、愛百草投資有限公司 1.61%、花草之愛有限公司 1.61%；部分主要股東間為同一代表人或二親等關係。子公司／採權益法投資包括霈曼國際股份有限公司、霈博生醫股份有限公司、Shine Style Ltd.、上海霈曼生物科技有限公司等。2026-03-12 公司公告 2025 年度合併獲利約新台幣 1.499 億元、EPS 6.82 元；2026-05-12 公告 2026 年第一季營收約 1.95 億元、營業毛利 1.12 億元、營業利益 8,368 萬元、稅後淨利 7,228 萬元、EPS 3.29 元；2026-06-16 股東常會通過 2025 年度盈餘分配，每股現金股利 3 元。

Business

霈方核心業務為美容保養護膚品與醫美銷售及勞務。2024 年報揭露 2024 年營收淨額 5.837 億元，其中美容保養護膚品 4.506 億元、占 77.02%；醫美銷售及勞務 1.310 億元、占 22.45%；其他 204 萬元、占 0.35%。2023 年美容保養護膚品占 93.42%、醫美銷售及勞務占 6.58%，顯示 2024 年醫美通路／醫材／設備租賃與後勤服務比重大幅提升。主要產品與品牌包括 EDN／envie de neuf 茵蝶高端保養品牌、NU+derma 新德曼肌因美容保養品牌、L'HERBOFLORE 蕾舒翠全方位美容與面膜／機能食品品牌，以及公司官網揭露的 Clinics 醫美診所、Wellness 內外保養、OEM/ODM 代工服務、Precision Medicine 精準醫療等服務項目。產品用途以臉部護膚為主，功效訴求包括抗老、保濕、美白、防曬、清潔、面膜、安瓶、乳霜、精華液、機能性食品、身體護理與醫美術後修護等。商業模式包括自有品牌開發、線下百貨專櫃與街邊店、線上品牌官網與電商、會員經營、醫美診所合作、商標授權、醫療器材銷售、儀器設備租賃、展店規劃與顧問諮詢服務。2024 年銷售地區高度集中台灣，台灣營收 5.8335 億元、占 99.94%，其他地區僅 0.06%。主要終端客戶為台灣一般消費者、會員、百貨／街邊店顧客、電商消費者及合作醫美診所；2024 年有一名關係人客戶 F 占銷貨淨額 22.73%，公司說明該客戶為醫美通路合作對象，其餘百貨、街邊店、經銷代理與個人消費者較分散。產品製造方面，公司揭露除自主工廠生產外，也委託通過化妝品 GMP 與 ISO22716 國際品質系統認證的化妝品大廠製造，劑型包含乳液、乳霜、精華液、化妝水、洗劑、眼面膜液、去角質膠、油膏與精油等。

Outlook 2025–2028

2025 至 2028 年展望以醫美服務轉型、全通路會員經營與高端美容保養新品為主要動能。成長動能方面，公司 2024 年報明確列出長短期計畫：增加醫學美容診所合作家數、提供醫美產業專業諮詢與服務、強化電商與虛實通路整合、優化百貨門店櫃點、整合組織與成本結構、與國內外實驗室及全球保養產業合作夥伴開發符合醫美合作通路需求的保養品，並布局全方位大健康產業。2025 年公司已延續轉型成果，2025 全年 EPS 6.82 元，2026 Q1 EPS 3.29 元，顯示醫美通路與費用結構改善在短期財務表現上已有明顯貢獻。新產品／新技術方面，公司年報揭露自 2024 年起投入植物外泌體保養品配方設計與功效驗證，預計 2025 年推出；另持續研發肌膚微生物保養、藍光防護、無水美容保養、植物萃取、抗氧化、保濕屏障、胜肽與高機能成分產品，並發展機能性食品與大健康產品。產業趨勢方面，公司年報引用市場資料指出全球化妝品市場 2024 年約 3,359.5 億美元，2025 年估 3,546.8 億美元，2032 年估 5,562.1 億美元，2025-2032 CAGR 約 6.64%；醫美產業趨勢則受亞太需求、社群媒體、AI 科技、Z 世代與年輕族群滲透率提升帶動，2028 前仍具成長想像。2025-2028 的關鍵觀察點包括：醫美合作診所數與單店貢獻是否擴大、醫美醫材／設備租賃／商標授權是否維持高成長、既有美容保養品營收是否止穩、電商與 CRM 是否提升回購率、百貨櫃點優化是否提升坪效、植物外泌體與機能食品等新品是否能帶動毛利與會員黏著度。主要風險包括：台灣市場營收占比接近 100% 帶來區域集中風險；2024 年關係人客戶 F 占銷貨 22.73% 帶來醫美通路客戶集中風險；醫材採購與合作診所擴張涉及法規、醫療品質、品牌聲譽與合約風險；美容保養品市場品牌眾多且競爭激烈；產品具效期且生命週期短，存貨跌價為會計師列示的關鍵查核事項；銷售櫃點員工流動率、百貨人流、消費景氣、電商流量成本、原物料與包材價格、外匯及跨境實驗室合作成本均可能影響獲利。2026-2028 的具體營收與 EPS 數字公司未公開正式長期指引，本段屬依公司公開計畫、已公告財報與產業趨勢作成的研究推估。

Supply Chain

Upstream

化妝品原料／物料／包材供應商年報揭露霈方所屬保養品產業上游包含原料、物料、包材供應商、半成品製造商與裝填容器製造商；未揭露具名供應商，故 stock_id 設為 null。
通過化妝品 GMP 與 ISO22716 認證之化妝品代工廠公司除自主工廠生產外，委託符合 GMP 與 ISO22716 的化妝品大廠製造乳劑、液劑、油膏、精油等產品；年報未揭露具名代工廠，故 stock_id 設為 null。
法國、美國、日本、韓國實驗室與專利原料／研發合作夥伴公司研發部門與海外實驗室合作，分析國際新原料與作用機制，應用植物萃取、抗氧化、保濕屏障、植物幹細胞、微生物保養、藍光防護與植物外泌體等技術；未揭露具名公司，故 stock_id 設為 null。
供應商C、供應商D、供應商E（未揭露名稱） 2024 年報指出供應商 C、D、E 為醫美醫材廠商，公司因 2024 年積極開拓醫美通路市場而增加醫材進貨；年報以代號揭露，無法確認是否上市櫃。

Downstream

客戶F（未揭露名稱） 2024 年報揭露客戶 F 為關係人且為醫美通路合作對象，2024 年銷貨金額約新台幣 1.327 億元、占銷貨淨額 22.73%；名稱未揭露，無法確認是否上市櫃。
合作醫學美容診所公司醫美銷售及勞務包含醫美診所商標授權、醫療器材銷售、儀器設備租賃、商圈評估、展店規劃及顧問諮詢服務；合作診所多未逐一揭露，stock_id 設為 null。
百貨經營體系與實體門店通路公司傳統美容保養事業透過百貨專櫃、街邊店與門市 POS 直接面向終端消費者；年報表示個人消費者人數多且分散，未揭露特定百貨或門市通路公司。
線上品牌官網與電商平台公司積極拓展品牌購物官網、電商與社群導流，落實 OMO 虛實整合；未揭露具名平台或營收占比，stock_id 設為 null。
經銷及代理商年報揭露公司透過經銷及代理商提供美容服務及產品銷售；未揭露具名公司，stock_id 設為 null。

Competitors

麗豐-KY 4137 台股上市公司，經營 CHLITINA 克麗緹娜美容連鎖、專業美容護膚品與居家保養產品，與霈方在美容保養品、連鎖美容與會員服務市場具競爭關係。
佐登-KY 4190 台股掛牌美容保養集團，經營佐登妮絲美容加盟、保養品與海外美容／醫美複合店，與霈方在美容服務、保養品與會員經營上具競爭關係。
美吾華 1731 台股上市公司，自有品牌美吾髮並具消費品與醫藥通路，與霈方在台灣美容保養／個人護理品牌與通路端部分重疊。
雙美 4728 台股上櫃生技醫材公司，主力為膠原蛋白植入劑與醫學美容相關醫材，與霈方的醫美通路、醫材銷售與醫美服務布局具部分競合關係。
大江 8436 台股上市生技公司，主攻保健食品、美容保養及機能產品 ODM/OEM；霈方發展機能性食品與美容保養新品時，與其在產品開發與代工生態中具部分競合關係。

Sources（16）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
Excess return is measured against the TAIEX total-return index (dividends included).
Valuation regime and percentile stats use an expanding own-history window (no future data).
Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.